1. Home
  2. PCVX vs CYTK Comparison

PCVX vs CYTK Comparison

Compare PCVX & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PCVX
  • CYTK
  • Stock Information
  • Founded
  • PCVX 2013
  • CYTK 1997
  • Country
  • PCVX United States
  • CYTK United States
  • Employees
  • PCVX N/A
  • CYTK N/A
  • Industry
  • PCVX Biotechnology: Pharmaceutical Preparations
  • CYTK Biotechnology: Pharmaceutical Preparations
  • Sector
  • PCVX Health Care
  • CYTK Health Care
  • Exchange
  • PCVX Nasdaq
  • CYTK Nasdaq
  • Market Cap
  • PCVX 4.0B
  • CYTK 4.6B
  • IPO Year
  • PCVX 2020
  • CYTK 2004
  • Fundamental
  • Price
  • PCVX $40.80
  • CYTK $59.65
  • Analyst Decision
  • PCVX Strong Buy
  • CYTK Strong Buy
  • Analyst Count
  • PCVX 8
  • CYTK 15
  • Target Price
  • PCVX $114.17
  • CYTK $76.73
  • AVG Volume (30 Days)
  • PCVX 1.5M
  • CYTK 1.7M
  • Earning Date
  • PCVX 11-05-2025
  • CYTK 11-05-2025
  • Dividend Yield
  • PCVX N/A
  • CYTK N/A
  • EPS Growth
  • PCVX N/A
  • CYTK N/A
  • EPS
  • PCVX N/A
  • CYTK N/A
  • Revenue
  • PCVX N/A
  • CYTK $85,738,000.00
  • Revenue This Year
  • PCVX N/A
  • CYTK $363.61
  • Revenue Next Year
  • PCVX N/A
  • CYTK $64.08
  • P/E Ratio
  • PCVX N/A
  • CYTK N/A
  • Revenue Growth
  • PCVX N/A
  • CYTK 2635.74
  • 52 Week Low
  • PCVX $27.66
  • CYTK $29.31
  • 52 Week High
  • PCVX $116.00
  • CYTK $64.13
  • Technical
  • Relative Strength Index (RSI)
  • PCVX 47.89
  • CYTK 54.38
  • Support Level
  • PCVX $43.12
  • CYTK $54.30
  • Resistance Level
  • PCVX $45.90
  • CYTK $64.13
  • Average True Range (ATR)
  • PCVX 1.86
  • CYTK 2.50
  • MACD
  • PCVX -0.59
  • CYTK -0.42
  • Stochastic Oscillator
  • PCVX 15.01
  • CYTK 54.37

About PCVX Vaxcyte Inc.

Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Share on Social Networks: